- Answer each of the 7 symptom questions (Q1–Q7) by selecting the frequency that best describes your experience over the past month. Tap or click the numbered box corresponding to your answer.
- All 7 questions must be answered before the result appears. There are no right or wrong answers — honesty produces the most useful score.
- Optionally, answer the Quality of Life item (QoL) at the bottom. This item is scored separately and not added to the IPSS total, but it is an important driver of treatment decisions.
- The result box shows your total score, severity band (Mild / Moderate / Severe), voiding and storage subscores, and a recommended next step.
- Use Print / Save as PDF to print a report for your physician. Bring the report to your next urology or nephrology appointment.
All computation runs in your browser; no values are stored or transmitted.
When to Use
Use the IPSS when evaluating any man with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH), and to monitor response to treatment at follow-up visits. The IPSS is the standard grading instrument recommended by the American Urological Association (AUA) and the European Association of Urology (EAU) for all men presenting with LUTS. It is particularly important in nephrology because obstructive uropathy from BPH is a reversible but often overlooked cause of CKD progression and acute kidney injury in older men.
Appropriate population
Men with LUTS (frequency, urgency, weak stream, incomplete emptying, nocturia, hesitancy, or intermittency) over the past month. Also used to monitor treatment response — repeat the IPSS at each urology or nephrology follow-up visit and compare scores over time. In CKD patients, an elevated IPSS with a rising creatinine should prompt measurement of post-void residual urine and bladder imaging to rule out obstructive nephropathy.
When NOT to rely on it alone
The IPSS measures symptom burden, not anatomical obstruction or urodynamic function. A high IPSS can occur with detrusor overactivity, urethral stricture, neurogenic bladder, or prostate cancer — not only BPH. Always pair the IPSS with post-void residual ultrasound, PSA, kidney function tests, and urinalysis. A severe IPSS (20–35) in a man with worsening kidney function is a urology emergency — do not wait.
Pearls & Pitfalls
The QoL item often drives treatment more than the score
A man with a moderate IPSS of 14 who rates his QoL as 5 (Unhappy) is experiencing far greater distress than his numeric score suggests and may strongly prefer treatment. Conversely, a man with an IPSS of 16 who rates his QoL as 2 (Mostly satisfied) may be comfortable with watchful waiting. Always present the QoL item to the patient before recommending a management path.
Serial scoring is more valuable than a single score
A clinically meaningful change in IPSS is ≥3 points. Document scores at baseline and at every follow-up to track treatment response. An alpha-blocker that produces a 5-point IPSS reduction is working; one that produces no change after 6 weeks should be reconsidered. Bring your most recent IPSS report to every urology and nephrology appointment.
Pitfalls
(1) A high IPSS does not diagnose BPH — rule out prostate cancer (PSA), urethral stricture, neurogenic bladder, and urinary tract infection first. (2) Severe IPSS + rising creatinine in an older man is a potential obstructive nephropathy emergency — order a renal ultrasound and post-void residual immediately, and refer urgently. (3) The IPSS was validated in men and its applicability in women with LUTS is limited — validated female LUTS scores exist for that population. (4) Q7 scores nocturia 0–5; a score of 5 means 5+ voids per night, which is clinically significant and associated with fall risk and sleep deprivation independent of BPH.
Why Use It
BPH affects over 50% of men over 60 and over 90% of men over 80. Left untreated, moderate-to-severe LUTS from BPH can progress to acute urinary retention, recurrent urinary tract infections, bladder wall thickening, bilateral hydroureteronephrosis, and obstructive nephropathy — an underrecognized cause of end-stage kidney disease. The IPSS quantifies the symptom burden in a standardized, reproducible way that removes ambiguity from clinical conversations: a score of 18 is objectively "moderate," a reduction from 22 to 12 after alpha-blocker therapy is a meaningful 10-point improvement, and a score of 25 tells a urologist that surgical evaluation is overdue. The quality-of-life item (Question 8) adds the patient's subjective burden, which sometimes drives treatment decisions more than the total score alone.
International Prostate Symptom Score (IPSS)
Answer all 7 symptom questions based on your experience over the past month. There are no right or wrong answers — honest responses give the most useful result. The quality-of-life item (QoL) is optional but adds important context for treatment decisions.
Not at all
Less than 1 in 5 times
Less than half the time
About half the time
More than half the time
Almost always
⚕ Bring your score to your next appointment. Your IPSS guides treatment decisions and helps track whether medications are working. This tool does not replace clinical evaluation.
Next Steps
Use the result to support — not replace — clinical judgment.
- Interpret the value against the targets shown in the calculator and the Evidence section below, in the context of the full clinical picture.
- Trend serial measurements rather than acting on a single result; confirm abnormal or unexpected values before changing management.
- Apply the relevant KDIGO / specialty-guideline threshold and document the indication.
- Escalate or refer to nephrology when results are out of range, rapidly changing, or discordant with the clinical picture — and discuss the implications with the patient.
Evidence & References
Formula & Equations
IPSS questions and subscores
| Q# | Question (abbreviated) | Subscore | Score range |
|---|---|---|---|
| Q1 | Incomplete emptying — sensation of not emptying bladder completely | Storage | 0–5 |
| Q2 | Frequency — urinating again within 2 hours | Storage | 0–5 |
| Q3 | Intermittency — stopping and starting several times while urinating | Voiding | 0–5 |
| Q4 | Urgency — difficulty postponing urination | Storage | 0–5 |
| Q5 | Weak stream | Voiding | 0–5 |
| Q6 | Straining — having to push or strain to begin urination | Voiding | 0–5 |
| Q7 | Nocturia — times getting up to urinate at night | Storage | 0–5 |
| QoL | How would you feel spending the rest of your life with your urinary condition as-is? | Quality of Life (separate) | 0–6 |
Interpretation bands
| Total score | Severity | Recommended approach |
|---|---|---|
| 0–7 | Mild BPH | Watchful waiting; lifestyle modifications (fluid timing, reduce caffeine/alcohol, bladder training); re-score in 6–12 months or sooner if symptoms worsen |
| 8–19 | Moderate BPH | Medical treatment recommended — alpha-blockers (tamsulosin, silodosin) first-line; consider 5-alpha reductase inhibitor for large prostates; check post-void residual urine and creatinine; urology referral appropriate |
| 20–35 | Severe BPH | Urgent urology referral; combination medical therapy or surgical evaluation (TURP, laser prostatectomy, or minimally invasive procedure); kidney function (creatinine, eGFR) and bladder ultrasound essential |
Voiding subscore (Q3 + Q5 + Q6): max 15. Storage subscore (Q1 + Q2 + Q4 + Q7): max 20. A QoL score of 4 or higher (Mostly dissatisfied, Unhappy, or Terrible) weighs strongly toward active treatment regardless of the total IPSS. The IPSS is identical to the AUA Symptom Index — the QoL item was added by the WHO to form the IPSS.
Evidence & References
The International Prostate Symptom Score was developed from the American Urological Association (AUA) Symptom Index by Barry et al. (1992) from a committee of urologists, epidemiologists, and patients. The QoL item was added by the World Health Organization to create the IPSS. The instrument has been validated in over 50 languages and adopted as the standard BPH grading tool by the AUA, EAU, and International Consultation on Urological Diseases (ICUD). Its use is endorsed in nephrology because obstructive uropathy from BPH is a leading reversible cause of CKD progression in older men.
- Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549–1557.
- Cockett AT, Barry MJ, Holtgrewe HL, et al. Indications for treatment of benign prostatic hyperplasia. The AUA Study Group. Cancer. 1992;70(1 Suppl):280–283.
- Roehrborn CG, McConnell JD, Barry MJ, et al. AUA guideline on management of benign prostatic hyperplasia. J Urol. 2003;170(2 Pt 1):530–547.
